Virtu Financial LLC Outlook Therapeutics, Inc. Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	BUY	$0.22 - $0.66 $14,992 - $44,976	68,146 New	68,146 $27,000
Q4 2022 Feb 15, 2023	BUY	$0.87 - $1.33 $32,570 - $49,791	37,437 New	37,437 $40,000
Q2 2022 Aug 09, 2022	BUY	$0.91 - $2.01 $19,218 - $42,449	21,119 New	21,119 $22,000
Q3 2021 Nov 12, 2021	SELL	$2.12 - $2.76 $29,989 - $39,042	-14,146 Closed	0 $0
Q2 2021 Sep 17, 2021	SELL	$1.78 - $2.76 $5,704 - $8,845	-3,205 Reduced 18.47%	14,146 $35,000
Q1 2021 May 19, 2021	SELL	$0.94 - $3.31 $87,964 - $309,746	-93,579 Reduced 84.36%	17,351 $39,000
Q4 2020 Feb 24, 2021	BUY	$0.7 - $1.58 $63,076 - $142,372	90,109 Added 432.78%	110,930 $144,000
Q3 2020 Dec 11, 2020	BUY	$0.61 - $1.6 $12,700 - $33,313	20,821 New	20,821 $15,000
Q2 2020 Aug 07, 2020	SELL	$0.56 - $1.41 $32,403 - $81,586	-57,863 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$0.53 - $1.59 $1,297 - $3,893	2,449 Added 4.42%	57,863 $34,000
Q3 2019 Nov 20, 2019	BUY	$1.32 - $2.63 $73,146 - $145,738	55,414 New	55,414 $83,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.